Author: Singh, Satyam; Sk, Md Fulbabu; Sonawane, Avinash; Kar, Parimal; Sadhukhan, Sushabhan
Title: Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNAâ€dependent RNA polymerase (RdRp) inhibition: an in-silico analysis Cord-id: 9auriv17 Document date: 2020_7_28
ID: 9auriv17
Snippet: The sudden outburst of Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a massive threat to global public health. Currently, no therapeutic drug or vaccine exists to treat COVID-19. Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. RNAâ€dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug de
Document: The sudden outburst of Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a massive threat to global public health. Currently, no therapeutic drug or vaccine exists to treat COVID-19. Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. RNAâ€dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. Interestingly, several plant-derived polyphenols effectively inhibit the RdRp of other RNA viruses. More importantly, polyphenols have been used as dietary supplementations for a long time and played beneficial roles in immune homeostasis. We were curious to study the binding of polyphenols with SARS-CoV-2 RdRp and assess their potential to treat COVID-19. Herein, we made a library of polyphenols that have shown substantial therapeutic effects against various diseases. They were successfully docked in the catalytic pocket of RdRp. The investigation reveals that EGCG, theaflavin (TF1), theaflavin-3’-O-gallate (TF2a), theaflavin-3’-gallate (TF2b), theaflavin 3,3'-digallate (TF3), hesperidin, quercetagetin, and myricetin strongly bind to the active site of RdRp. Further, a 150-ns molecular dynamic simulation revealed that EGCG, TF2a, TF2b, TF3 result in highly stable bound conformations with RdRp. The binding free energy components calculated by the MM-PBSA also confirm the stability of the complexes. We also performed a detailed analysis of ADME prediction, toxicity prediction, and target analysis for their druggability. Overall, our results suggest that EGCG, TF2a, TF2b, TF3 can inhibit RdRp and represent an effective therapy for COVID-19. Communicated by Ramaswamy H. Sarma
Search related documents:
Co phrase search for related documents- acceptor donor and acute respiratory: 1, 2, 3, 4, 5, 6, 7
- acceptor donor and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5
- acceptor donor and liver small intestine: 1
- active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and acute toxicity: 1
- active site and admet profile: 1, 2
- active site and admet study: 1
- active site domain and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9
- active site domain and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory and adme prediction: 1, 2, 3
- acute respiratory and admet profile: 1, 2, 3
- acute respiratory and admet study: 1, 2, 3, 4, 5
- acute respiratory and liver small intestine: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome coronavirus and adme prediction: 1, 2, 3
- acute respiratory syndrome coronavirus and admet profile: 1, 2
- acute respiratory syndrome coronavirus and admet study: 1, 2, 3, 4
- acute respiratory syndrome coronavirus and liver small intestine: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date